Cargando…

Evaluating initial responses to brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: a retrospective, single-center, observational study

Our retrospective, single-center, observational study aimed to evaluate the initial responses to intravitreal injection of brolucizumab (IVBr) in patients undergoing anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME). In total, 23 eyes of 20 patients with DME tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirano, Takao, Kumazaki, Akane, Tomihara, Ryuji, Ito, Syun, Hoshiyama, Ken, Murata, Toshinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322981/ https://www.ncbi.nlm.nih.gov/pubmed/37407660 http://dx.doi.org/10.1038/s41598-023-37726-5

Ejemplares similares

Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema
por: Hirano, Takao, et al.
Publicado: (2022)

Contralateral Effect following Intravitreal Brolucizumab Injection in Diabetic Macular Edema
por: Chakraborty, Somnath, et al.
Publicado: (2022)

Morphological Changes in the Foveal Avascular Zone after Panretinal Photocoagulation for Diabetic Retinopathy Using OCTA: A Study Focusing on Macular Ischemia
por: Hoshiyama, Ken, et al.
Publicado: (2022)

Brolucizumab for macular degeneration
Publicado: (2020)

Glycemic Control after Initiation of Anti-VEGF Treatment for Diabetic Macular Edema
por: Oshima, Hideyuki, et al.
Publicado: (2022)

Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
por: Garweg, Justus G., et al.
Publicado: (2023)

Optical coherence tomography angiography findings before and after onset of foveal retinal neovascularization in diabetic retinopathy
por: Hirano, Takao, et al.
Publicado: (2022)

Brolucizumab—another anti-VEGF or beyond
por: Sharma, Ashish, et al.
Publicado: (2020)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA
por: Hirano, Takao, et al.
Publicado: (2018)

Impact of local COVID-19 alert levels on rhegmatogenous retinal detachment
por: Chiku, Yoshiaki, et al.
Publicado: (2023)

Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

New Strategies for Treatment of Diabetic Macular Edema
por: Takamura, Yoshihiro, et al.
Publicado: (2018)

Anti-VEGF for the Management of Diabetic Macular Edema
por: Stefanini, Francisco Rosa, et al.
Publicado: (2014)

Short-term outcomes following treatment of recalcitrant cystoid macular edema secondary to radiation maculopathy using intravitreal brolucizumab
por: Corradetti, Giulia, et al.
Publicado: (2020)

Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema
por: Hirano, Takao, et al.
Publicado: (2021)

Diabetic macular edema: it is more than just VEGF
por: Singer, Michael A., et al.
Publicado: (2016)

Brolucizumab: Evaluation of Compassionate Use of a Complex Anti-VEGF Therapy
por: Murray, Julianna E, et al.
Publicado: (2021)

Bilateral blindness after uneventful brolucizumab injection for macular degeneration
por: Barchichat, Ilan, et al.
Publicado: (2022)

Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)
por: Van Cleemput, Liesbeth, et al.
Publicado: (2023)

Morphological Macular Changes Under Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration Refractory to Previous Anti-VEGF Treatment Compared with Treatment-Naive Eyes
por: William, Antony, et al.
Publicado: (2023)

Temporal Change in Anterior Chamber Depth after Combined Vitrectomy and Cataract Surgery Using Different Sizes of Intraocular Lens
por: Takahashi, Yoshiaki, et al.
Publicado: (2022)

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi, Nicolas A, et al.
Publicado: (2019)

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies
por: Karasavvidou, Evdoxia-Maria, et al.
Publicado: (2022)

One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
por: Coney, Joseph M, et al.
Publicado: (2023)

Brolucizumab and immunogenicity
por: Sharma, Ashish, et al.
Publicado: (2020)

Vitreomacular interface after anti-VEGF injections in diabetic macular edema
por: Veloso, Carlos E., et al.
Publicado: (2021)

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
por: Maggio, Emilia, et al.
Publicado: (2022)

Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes
por: Eissing, Thomas, et al.
Publicado: (2021)

Outer retinal tubulation in diabetic macular edema following anti-VEGF treatment
por: Al-Halafi, Ali M
Publicado: (2015)

Dexamethasone Implant in Patients with Diabetic Macular Edema Resistant to Anti-VEGF Therapy
por: Nalçacı, Serhad, et al.
Publicado: (2019)

Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review
por: Distefano, Laura N., et al.
Publicado: (2017)

Side Effects of Brolucizumab
por: Motevasseli, Tahmineh, et al.
Publicado: (2021)

Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration
por: Avaylon, Jaycob, et al.
Publicado: (2020)

Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study
por: Bilgic, Alper, et al.
Publicado: (2021)

Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections
por: Gigon, Anthony, et al.
Publicado: (2022)

The effect of intravitreal brolucizumab on choroidal thickness in patients with neovascular age-related macular degeneration
por: Bae, Ki Woong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2c3jiqs7s23noos0nr4f4lvls2